-
Australia Opens The Door for SKY-0515: Skyhawk Seeks Provisional Approval for Its Oral HD Drug
Latest News
-
The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy
⏱️ 10 min read | The FDA wants more data before approving AMT-130 for Huntington’s disease in the U.S. On March 2026, uniQure shared in an update that current Phase 1/2 data weren’t enough for the agency. A new randomized, sham-controlled trial may be required.
-
EuroBuzz 2014: day two
HDBuzz reports on the second day of science at the European HD Network meeting in Barcelona
-
EuroBuzz 2014: day one
Highlights from the opening day of the 2014 European Huntington's Disease network in Barcelona, Spain
-
Going toe-to-toe with tau: new insights into the chemical basis of Huntington’s disease
Does tau protein – which causes problems in other neurodegenerative diseases – contribute to Huntington's disease?
-
New results bring BDNF therapies into focus
Some unexpected findings suggest new ways to aim at an old target in HD
-
2CARE study of coenzyme Q for Huntington's disease ends in disappointment
The largest ever HD drug trial, testing coenzyme Q10, is halted for 'futility'. What does that mean for HD research?
-
A starring role for astrocytes in Huntington's disease?
Brain cells called astrocytes might play a bigger role than previously thought in Huntington's disease
-
HD mice provide a useful failure
Can drug trials that fail be helpful? A HD mouse study provides solid evidence of an approach that doesn't help HD
-
Illuminating the progression of Huntington’s disease
Researchers have used mice with glowing brain cells to decipher the first steps of neurodegeneration
-
Jumping genes: Huntington's disease protein invades brain transplants
A long-term study of the brains of HD patients who received grafts of fetal tissue reveals a surprising result
-
The brain in Huntington's disease: greater than the sum of its parts?
An important new study asks the question: what parts of the brain might need most help in HD?
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
